Concepedia

Mads Bjelke

MB

Statistics

Publications

4

Citations

70

H-Index

4

Active since

2019

Affiliations

Novo Nordisk (Denmark)(Current)

Mads Bjelke is an author at Novo Nordisk (Denmark) specializing in medicine, pharmacology, and histopathological evaluation.

Publications per year

2019–2022

4

Publications

4

A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys

Brian Lauritzen, Mads Bjelke, Olle Björkdahl et al. · Journal of Thrombosis and Haemostasis · 2022 · 37 citations · Full text

Medicine, Hematology, Pharmacology +13

Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects

Hans Helleberg, Mads Bjelke, Birgitte Bentz Damholt et al. · European Journal of Pharmaceutical Sciences · 2021 · 13 citations · Full text

Medicine, Endocrinology, Pharmacology +13

Administration of recombinant FVIIa (rFVIIa) to concizumab‐dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits

Brian Lauritzen, Janne Olling, Kristin L. Abel et al. · Journal of Thrombosis and Haemostasis · 2019 · 10 citations · Full text

Veterinary Medicine, Pharmacology, Rabbit Medicine +1

Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats

Hans Helleberg, Rikke Hvid Lindecrona, Peter Thygesen et al. · European Journal of Pharmaceutical Sciences · 2021 · 10 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

1–4 of 4